Table 2.
Characteristics of pDILI Type 1 cases (BTS/ATS criteria) and controls
| Characteristic | Controls | DILI cases | ||
|---|---|---|---|---|
| Median (IQR) | Median (IQR) | P-value† | ||
| Baseline ALT (IU/L) | 19 (14–29), n = 185 | 24 (17–32), n = 77 | 0.03 | |
| Baseline ALP (IU/L) | 86 (71–102), n = 187 | 98 (75–135), n = 77 | 0.03 | |
| Baseline bilirubin (umol/L) | 8 (5–10), n = 185 | 8 (6–12), n = 77 | 0.28 | |
| Weight (kg) | 61.2 (54.5–69.6), n = 178 | 53.9 (48.0–65.0), n = 74 | 0.001 | |
| Rifampicin dose per kg | (if given) | 9.68 (8.62–10.7), n = 178 | 9.98 (9.00–11.1), n = 74 | 0.17 |
| Isoniazid dose per kg | (if given) | 4.85 (4.31–5.45), n = 178 | 5.57 (4.62–6.25), n = 74 | <0.001 |
| Pyrazinamide dose per kg | (if given) | 24.4 (21.4–27.5), n = 178 | 25.8 (22.7–29.8), n = 74 | 0.05 |
| Moxifloxacin dose per kg | (if given) | 6.15 (5.71–7.04), n = 21 | 7.67 (5.71–8.00), n = 10 | 0.20 |
| % (fraction) | % (fraction) | |||
| HIV positive | 2.2 (4/185) | 7.3 (5/69) | 0.06 | |
| HCV positive | 1.7 (3/179) | 1.4 (1/73) | 1.00 | |
| HBV positive | 2.2 (4/180) | 0.0 (0/74) | 0.33 | |
| Alcohol consumptiona | Nil | 93.3 (167/179) | 71.4 (40/56) | <0.001 |
| Any | 6.7 (12/179) | 28.6 (16/56) | ||
| Chronic Liver Disease | 2.2 (4/186) | 3.9 (3/77) | 0.42 | |
† P-values from Kruskal-Wallis test (medians), Fisher’s exact test (proportions)
a Most patients drank no alcohol and only 1 patient (male) drank in excess of 21 units/week; given the small number of high alcohol intake, this was analysed as no intake versus any intake of alcohol